Cargando…
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649581/ http://dx.doi.org/10.1186/2051-1426-3-S2-P202 |
| _version_ | 1782401388379111424 |
|---|---|
| author | Dillman, Robert O McClay, Edward Amatruda, Thomas Semeniuk, George Haskins, Clark Weber, Robert Burtzo, David DePriest, Carol Carbonell, Denysha Cornforth, Andrew |
| author_facet | Dillman, Robert O McClay, Edward Amatruda, Thomas Semeniuk, George Haskins, Clark Weber, Robert Burtzo, David DePriest, Carol Carbonell, Denysha Cornforth, Andrew |
| author_sort | Dillman, Robert O |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4649581 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46495812015-11-24 Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines Dillman, Robert O McClay, Edward Amatruda, Thomas Semeniuk, George Haskins, Clark Weber, Robert Burtzo, David DePriest, Carol Carbonell, Denysha Cornforth, Andrew J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4649581/ http://dx.doi.org/10.1186/2051-1426-3-S2-P202 Text en Copyright © 2015 Dillman et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Dillman, Robert O McClay, Edward Amatruda, Thomas Semeniuk, George Haskins, Clark Weber, Robert Burtzo, David DePriest, Carol Carbonell, Denysha Cornforth, Andrew Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title | Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title_full | Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title_fullStr | Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title_full_unstemmed | Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title_short | Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| title_sort | superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in macvac randomized phase ii trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649581/ http://dx.doi.org/10.1186/2051-1426-3-S2-P202 |
| work_keys_str_mv | AT dillmanroberto superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT mcclayedward superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT amatrudathomas superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT semeniukgeorge superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT haskinsclark superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT weberrobert superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT burtzodavid superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT depriestcarol superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT carbonelldenysha superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines AT cornforthandrew superiorityofdendriticcellvaccinevstumorcellvaccinesurvivalbystratificationsubsetsinmacvacrandomizedphaseiitrialofpatientspecificvaccinesutilizingantigensfromautologousmelanomatumorcelllines |